Work

Supplementary Table 1 from Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1. Summary of Interval Systemic Anticancer Therapies Received by ALK-Positive Patients Between Crizotinib and Ceritinib

DOI: 10.1158/1078-0432.22460661.v1

Authors: Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361919665

Cites:

Cited by:

Related to: 10